U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C8H14N4O5.ClH
Molecular Weight 282.682
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 5,6-DIHYDRO-5-AZACYTIDINE HYDROCHLORIDE

SMILES

Cl.NC1=NC(=O)N(CN1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O

InChI

InChIKey=MRFRLYAOBSTHHU-MVNLRXSJSA-N
InChI=1S/C8H14N4O5.ClH/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6;/h3-6,13-15H,1-2H2,(H3,9,10,11,16);1H/t3-,4-,5-,6-;/m1./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C8H14N4O5
Molecular Weight 246.2206
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

5,6-dihydro-5-azacytidine (DHAC) is a hydrolytically stable congener of 5-azacytidine. It exerts cytostatic action in vitro. DHAC induces DNA hypomethylation. DHAC inhibits DNA methyltransferase, thereby interfering with abnormal DNA methylation patterns that are associated with genetic instability in some tumor cells. Inhibition of this enzyme may restore expression of tumor-suppressor genes and result in antitumor activity. It was in phase II studies for the treatment of several cancers such as malignant melanoma, mesothelioma and others.

Approval Year

PubMed

PubMed

TitleDatePubMed
Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications.
2010-04-01
Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904.
2008-04
Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review.
2006-10-06
Hydralazine target: from blood vessels to the epigenome.
2006-02-28
Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines.
2006-01-31
Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method.
2006
Epigenetics of cervical cancer. An overview and therapeutic perspectives.
2005-10-25
Chemotherapy for malignant pleural mesothelioma: past results and recent developments.
2003-01-27
DNA methyltransferase inhibitors-state of the art.
2002-11
Inactivation of p16INK4a expression in malignant mesothelioma by methylation.
2002-11
Identification of active antiviral compounds against a New York isolate of West Nile virus.
2002-07
Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
1998-04-15
Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.
1997-06-01
A phase II study of 5,6-dihydro-5-azacytidine hydrochloride in disseminated malignant melanoma.
1993-06
Fetal hemoglobin gene activation in a phase II study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma.
1987-08-01
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:45:54 GMT 2025
Edited
by admin
on Mon Mar 31 17:45:54 GMT 2025
Record UNII
TA5S1BS78J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
5,6-DIHYDRO-5-AZACYTIDINE HYDROCHLORIDE
Systematic Name English
1,3,5-TRIAZIN-2(1H)-ONE, 4-AMINO-5,6-DIHYDRO-1-.BETA.-D-RIBOFURANOSYL-, MONOHYDROCHLORIDE
Preferred Name English
NSC-264880
Code English
Code System Code Type Description
EPA CompTox
DTXSID20977982
Created by admin on Mon Mar 31 17:45:54 GMT 2025 , Edited by admin on Mon Mar 31 17:45:54 GMT 2025
PRIMARY
CAS
62402-31-7
Created by admin on Mon Mar 31 17:45:54 GMT 2025 , Edited by admin on Mon Mar 31 17:45:54 GMT 2025
PRIMARY
FDA UNII
TA5S1BS78J
Created by admin on Mon Mar 31 17:45:54 GMT 2025 , Edited by admin on Mon Mar 31 17:45:54 GMT 2025
PRIMARY
PUBCHEM
151716
Created by admin on Mon Mar 31 17:45:54 GMT 2025 , Edited by admin on Mon Mar 31 17:45:54 GMT 2025
PRIMARY
NSC
264880
Created by admin on Mon Mar 31 17:45:54 GMT 2025 , Edited by admin on Mon Mar 31 17:45:54 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY